Limits...
SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma.

Chen D, Li Y, Wang L, Jiao K - Int J Breast Cancer (2015)

Bottom Line: We found 6-gene expression profile that can be used as such predictors.Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression.The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; Comprehensive Cancer Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

ABSTRACT
Breast cancer (BC) is the second most common cancer diagnosed in American women and is also the second leading cause of cancer death in women. Research has focused heavily on BC metastasis. Multiple signaling pathways have been implicated in regulating BC metastasis. Our knowledge of regulation of BC metastasis is, however, far from complete. Identification of new factors during metastasis is an essential step towards future therapy. Our labs have focused on Semaphorin 6D (SEMA6D), which was implicated in immune responses, heart development, and neurogenesis. It will be interesting to know SEMA6D-related genomic expression profile and its implications in clinical outcome. In this study, we examined the public datasets of breast invasive carcinoma from The Cancer Genome Atlas (TCGA). We analyzed the expression of SEMA6D along with its related genes, their functions, pathways, and potential as copredictors for BC patients' survival. We found 6-gene expression profile that can be used as such predictors. Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression. The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

No MeSH data available.


Related in: MedlinePlus

SEMA6D correlates with patient survival.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4417987&req=5

fig5: SEMA6D correlates with patient survival.

Mentions: SEMA6D Expression Correlates with Patients' Survival. In order to determine if SEMA6D and SEMA6D-related genes are correlated with overall patient survival, we filtered the significant gene list after SEMA6D-high versus SEMA6D-low expression comparison by choosing the top 10 most upregulated genes and top 10 most downregulated genes and conducted a survival analysis by using K-M methods. We found that 6 candidate genes were significantly associated with overall survival. These genes are SEMA6D, CLEC9A, C10orf107, DONSON, CHAC1, and TUBA1C. Two more genes COL4A6 and CBX2 genes are in borderline to be significant. A summary of these 8 genes is listed in Table 6 and Figure 5.


SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma.

Chen D, Li Y, Wang L, Jiao K - Int J Breast Cancer (2015)

SEMA6D correlates with patient survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4417987&req=5

fig5: SEMA6D correlates with patient survival.
Mentions: SEMA6D Expression Correlates with Patients' Survival. In order to determine if SEMA6D and SEMA6D-related genes are correlated with overall patient survival, we filtered the significant gene list after SEMA6D-high versus SEMA6D-low expression comparison by choosing the top 10 most upregulated genes and top 10 most downregulated genes and conducted a survival analysis by using K-M methods. We found that 6 candidate genes were significantly associated with overall survival. These genes are SEMA6D, CLEC9A, C10orf107, DONSON, CHAC1, and TUBA1C. Two more genes COL4A6 and CBX2 genes are in borderline to be significant. A summary of these 8 genes is listed in Table 6 and Figure 5.

Bottom Line: We found 6-gene expression profile that can be used as such predictors.Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression.The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; Comprehensive Cancer Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

ABSTRACT
Breast cancer (BC) is the second most common cancer diagnosed in American women and is also the second leading cause of cancer death in women. Research has focused heavily on BC metastasis. Multiple signaling pathways have been implicated in regulating BC metastasis. Our knowledge of regulation of BC metastasis is, however, far from complete. Identification of new factors during metastasis is an essential step towards future therapy. Our labs have focused on Semaphorin 6D (SEMA6D), which was implicated in immune responses, heart development, and neurogenesis. It will be interesting to know SEMA6D-related genomic expression profile and its implications in clinical outcome. In this study, we examined the public datasets of breast invasive carcinoma from The Cancer Genome Atlas (TCGA). We analyzed the expression of SEMA6D along with its related genes, their functions, pathways, and potential as copredictors for BC patients' survival. We found 6-gene expression profile that can be used as such predictors. Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression. The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

No MeSH data available.


Related in: MedlinePlus